FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy. PMID 39219495 · Clin Infect Dis · 2025-Mar-17 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS. PMID 38824910 · J Clin Endocrinol Metab · 2025-Mar-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer. PMID 40136373 · Curr Oncol · 2025-Mar-15 While the study is from a randomized Phase III trial (TROPiCS-02) with a drug intervention and original results for OS/PFS, this specific publication is a Q-TWiST analysis. It is a secondary, patient-preference and quality-of-life integrated analysis, not the primary or key secondary report of the time-to-event efficacy endpoint (OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. PMID 40037388 · Lancet · 2025-Mar-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial. PMID 40023176 · Lancet · 2025-Mar-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) study. PMID 39791502 · J Bone Miner Res · 2025-Mar-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial. PMID 39708914 · Neuropharmacology · 2025-Mar-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors. PMID 39577475 · Int J Radiat Oncol Biol Phys · 2025-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial. PMID 39486645 · Int J Radiat Oncol Biol Phys · 2025-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Randomized, Multicenter, Phase 2 Trial of Camrelizumab With or Without Metastasis-directed Stereotactic Body Radiation Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma. PMID 39454735 · Int J Radiat Oncol Biol Phys · 2025-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Predictive Model of Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia on Event-Free Survival: Data Analysis Based on Trial AAML0531. PMID 40150760 · Bioengineering (Basel) · 2025-Mar-14 The record describes a secondary analysis (predictive model development) of data from a Phase III RCT, not the original formal result report of the trial's primary efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review. PMID 40141261 · Int J Mol Sci · 2025-Mar-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A prospective randomized study of the efficacy of continuous active warming in patients undergoing laparoscopic gastrectomy. PMID 40087578 · BMC Gastroenterol · 2025-Mar-14 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Antisecretory factor as add-on treatment for newly diagnosed glioblastoma, IDH wildtype: study protocol for a randomized double-blind placebo-controlled trial. PMID 40083039 · Trials · 2025-Mar-13 方案论文未报告临床试验结果。 |
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Standard versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes after Whipple resection (SPARROW): a study protocol for a multicentre, open-label, randomised controlled trial. PMID 40083036 · Trials · 2025-Mar-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The long-term impact of single intraoperative instillation of pirarubicin after radical nephroureterectomy on local and systemic cancer control: a prospective, multicenter, randomized trial. PMID 40080123 · World J Urol · 2025-Mar-13 While the study is oncology, human, randomized, and reports a time-to-event endpoint (OS), the phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata. The deterministic review also flagged this uncertainty. Furthermore, the primary efficacy endpoint of the trial is intravesical recurrence (IVR), which is a local recurrence metric. The study reports no significant difference in OS, but OS is presented as a secondary or exploratory outcome, not the primary/key secondary time-to-event efficacy endpoint for which the trial was designed. Therefore, the core eligibility criteria of a Phase III/IIIb or II/III trial with a primary/key secondary time-to-event efficacy endpoint are not met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Quadratus lumborum block is feasible alternative to epidural block for postoperative analgesia after open radical cystectomy: surgical and oncological outcomes of a randomised clinical trial. PMID 40079670 · Scand J Urol · 2025-Mar-13 The study is excluded because it does not involve a drug-containing intervention and does not report a primary/key time-to-event efficacy endpoint (OS, PFS, etc.) with Kaplan-Meier or HR analysis. It is a trial of regional anesthesia techniques for postoperative pain management in bladder cancer surgery, focusing on analgesic and complication outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Radiotherapy quality assurance in the PROTECT trial - a European randomised phase III-trial comparing proton and photon therapy in the treatment of patients with oesophageal cancer. PMID 40079654 · Acta Oncol · 2025-Mar-13 The record describes a quality assurance sub-study within a phase III randomized trial. It does not report a drug intervention or a time-to-event efficacy endpoint, which are required for inclusion. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study. PMID 40079470 · Am J Gastroenterol · 2025-Mar-13 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial. PMID 39665649 · N Engl J Med · 2025-Mar-13 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
B
|
仅广召回影子组 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with DaxibotulinumtoxinA. PMID 40137906 · Toxins (Basel) · 2025-Mar-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The benefit and risk of addition of PD-1/PD-L1 inhibitors to chemotherapy for advanced cervical cancer: a phase 3 randomized controlled trials based meta-analysis. PMID 40075324 · BMC Cancer · 2025-Mar-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma. PMID 40072044 · Cancer Biol Med · 2025-Mar-12 The study is eligible for inclusion based on oncology, human subjects, phase 3, time-to-event endpoints, and drug intervention. However, it cannot be marked as eligible because the abstract and metadata do not provide explicit evidence of randomization, which is a required criterion for a randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. PMID 40069616 · BMC Cancer · 2025-Mar-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Sulfonylurea drugs for people with severe hemispheric ischemic stroke. PMID 40066941 · Cochrane Database Syst Rev · 2025-Mar-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial. PMID 39908052 · JAMA · 2025-Mar-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Negative Pressure Dressings to Prevent Surgical Site Infection After Emergency Laparotomy: The SUNRRISE Randomized Clinical Trial. PMID 39869330 · JAMA · 2025-Mar-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2. PMID 40163688 · Oncologist · 2025-Mar-10 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies. PMID 40139261 · Oncologist · 2025-Mar-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial. PMID 40088185 · Oncologist · 2025-Mar-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of adapted physical activity and diet counselling on health-related quality of life in women undergoing adjuvant breast cancer therapy. PMID 40064980 · Sci Rep · 2025-Mar-10 The study is a randomized, oncology trial with a drug-containing intervention, but the primary/ key secondary endpoints are health-related quality of life (HRQoL) and its analysis. The survival analysis for time to deterioration of HRQoL is presented as a methodological approach, not as a primary or key secondary efficacy endpoint for drug intervention. Therefore, it lacks the required primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703. PMID 39752608 · J Clin Oncol · 2025-Mar-10 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET). PMID 39586038 · J Clin Oncol · 2025-Mar-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer. PMID 39427229 · Oncologist · 2025-Mar-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Erratum: Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. PMID 39137378 · J Clin Oncol · 2025-Mar-10 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dummy run study for outlining and plan quality of intensity-modulated radiotherapy in elderly patients with newly diagnosed glioblastoma: The Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). PMID 40059195 · Radiat Oncol · 2025-Mar-09 The report is a protocol-focused quality assurance study (dummy run) for a phase III trial, not a report of trial efficacy results. It does not contain any time-to-event outcome data and the intervention is not drug-containing. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Selinexor in the treatment of liposarcoma: from preclinical evidence to clinical practice. PMID 40056309 · Med Oncol · 2025-Mar-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Transcutaneous Auricular Vagus Nerve Stimulation Reduces Inflammatory Biomarkers and May Improve Outcomes after Large Vessel Occlusion Strokes: Results of the Randomized Clinical Trial NUVISTA. PMID 40093228 · medRxiv · 2025-Mar-07 The trial is not oncology; it is a randomized trial of transcutaneous auricular vagus nerve stimulation (a device/neuromodulation) for ischemic stroke, not a drug intervention, and the primary/secondary endpoints are biomarkers and clinical scores, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial. PMID 40055382 · NPJ Breast Cancer · 2025-Mar-07 The study is a secondary biomarker analysis from a Phase III randomized trial in breast cancer, but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The endpoint analyzed is pathological complete response (pCR), which is a binary endpoint. Additionally, the specific drug intervention is not described in the abstract. Therefore, it does not meet the inclusion criteria for a drug-intervention Phase III/IIIb trial with a time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Non-inferiority and vaccine titer-confirmation studies of MMR vaccine (JVC-001; measles AIK-C, mumps RIT4385, and rubella Takahashi strains) in healthy 1-year-old Japanese children. PMID 39920023 · Vaccine · 2025-Mar-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Oral Intake of Hydrogen-Rich Jelly Intake on Gingival Inflammation: A Double-Blind, Placebo-Controlled and Exploratory Randomized Clinical Trial. PMID 40077138 · Healthcare (Basel) · 2025-Mar-06 The study is a randomized, placebo-controlled trial reporting primary results, but it is not an oncology study, does not involve a drug intervention, and lacks a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Screening to identify people with type 2 diabetes at risk of liver cancer in primary care: a randomised controlled trial protocol. PMID 40050060 · BMJ Open · 2025-Mar-06 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| CADOR (Capsaicin in neuropathic-like pain in digital osteoarthritis) study protocol: a multicentre randomised parallel-group trial. PMID 40050054 · BMJ Open · 2025-Mar-06 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Remibrutinib in Chronic Spontaneous Urticaria. PMID 40043237 · N Engl J Med · 2025-Mar-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis. PMID 40043236 · N Engl J Med · 2025-Mar-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tirzepatide for Obesity Treatment and Diabetes Prevention. PMID 39536238 · N Engl J Med · 2025-Mar-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial. PMID 41891861 · BJS Open · 2025-Mar-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comprehensive evaluation of tumor response better evaluates the efficacy of neoadjuvant chemotherapy and predicts the prognosis in gastric cancer - a post hoc analysis of a single-center randomized controlled trial. PMID 40045265 · BMC Cancer · 2025-Mar-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of peritoneal bladder flap in robot-assisted radical prostatectomy patients on lymphoceles: a prospective randomised trial. PMID 40044802 · World J Urol · 2025-Mar-05 The study is an oncology (prostate cancer), human, randomized, prospective trial with primary results. However, it is excluded because: 1) The intervention is a surgical technique modification (peritoneal flap fixation), not a drug-containing intervention. 2) The primary endpoint is a complication rate (lymphoceles requiring intervention), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR-based endpoint). 3) The study is not Phase III/IIIb or Phase II/III; no phase is specified but it is a definitive randomized trial, but the drug criterion is not met. The report is the primary result of the trial, not a subgroup, safety, or other analysis type. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X). PMID 40044198 · BMJ Open · 2025-Mar-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |